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In the present study, we used the human EA.hy926 endothelial cell line as the model system to investigate the effect of human serum
albumin (HSA) and its structural variants on cholesterol efflux. Initial studies showed that HSA promoted cholesterol efflux in a dose- and
time-dependent manner, reaching a plateau at 10 mg/ml at 90 min. As a control, gelatin displayed no significant effect on efflux, while HSA
was significantly more efficient than ovalbumin and bovine serum albumin (BSA) in promoting cholesterol efflux. Equal molar
concentrations of HSA and apolipoprotein A-I (apoA-I) showed that apoA-I had considerably higher efficiency in efflux. However, the
prevailing high plasma concentrations of HSA may compensate for its lower efflux rate compared to apoA-I. To characterize the mechanism
of HSA-mediated cholesterol efflux, we studied the effects of cAMP and temperature on efflux using both EA.hy926 endothelial cells and
murine RAW 264.7 macrophages. We found that HSA-mediated efflux occurred via a cAMP-independent and relatively temperature-
insensitive pathway. We next examined the nature of HSA–cholesterol interaction by comparing the effects of various HSA mutants to wild-
type HSA on cholesterol efflux. We found specific interactions between subdomains 2A and 3A and cholesterol, as indicated by the changes
in the efflux rate of various HSA mutants. In conclusion, our study provides evidence for the role of HSA in cholesterol efflux, and shows
that the substitution of specific amino acid residues in subdomains of 2A and 3A may be important structural determinants in its ability to
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Human serum albumin (HSA) is a major protein compo-
nent of plasma. It is mainly responsible for maintaining
plasma oncotic pressure and binding of various endogenous
and exogenous ligands including hormones, toxic metabo-
lites, and various drugs among other hydrophobic ligands
[1–3]. By binding to various ligands in circulation, HSA
modulates hormonal activity, toxicity of various endogenous
and exogenous substances, and drug availability. Various
ligand binding studies, including X-ray crystallography, on
HSA have shown that it has two major ligand binding sites
located in the subdomains of 2A and 3A [4–6]. Thyroxine,
bilirubin, warfarin, among many others, are examples of
HSA ligands that bind to these sites. Another possible
ligand may be cholesterol whose interaction with HSA has
not been investigated.ed.
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terol efflux from cultured human fibroblasts [7–9]. Also, an
animal study in rats showed that serum albumin played a
major role in cholesterol transport in circulation and esti-
mated approximately 24% of the nonesterified cholesterol
was bound to albumin [10]. These observations were pivotal
in pursuing our study. HSA, like high-density lipoprotein
(HDL), may participate in the reverse cholesterol transport
from peripheral cells. HSA-mediated cholesterol efflux may
have two important attributes, which may contribute to its
superior activity over the well-studied apolipoprotein A-I
(apoA-I)-mediated efflux. First, it has a higher capacity for
transport due to relatively high concentrations of HSA (660
AM) in human plasma compared to apoA-I (55 AM), and
secondly, its polymorphic forms may possess a higher
affinity for cholesterol. In regard to the second attribute,
HSA mutant proteins can be used as potential binding
agents to remove excess cholesterol from circulation as
similarly described for digitalis glycoside, bilirubin, and
warfarin [11–13]. Site-directed mutagenesis studies of HSA
have shown that various point mutations introduced into
major ligand binding domains of HSA induces significant
changes in its ligand binding capacity [13–16], with the
possible result of affecting metabolism of certain ligands.
The 2A and 3A subdomains of HSA have been shown to be
two major sites in hydrophobic ligand binding, such as fatty
acids, warfarin, bilirubin, and diazepam [17]. A number of
studies have shown that steroids bind to HSAwith moderate
binding affinity and that fatty acids can displace up to 50%
of steroids bound to HSA, indicating that steroids are likely
to bind in the 2A or 3A subdomain [18]. Since cholesterol is
a steroid, we hypothesized that all steroid molecules may
share the same binding domain of HSA. Thus, we used a
number of 2A and 3A subdomain mutants to study the
effects of various amino acid substitutions on cholesterol
efflux. Since several epidemiologic studies have shown an
inverse relationship between serum HSA levels and the
incidence of coronary heart disease (CHD) [19–25], one
of the aims of our cholesterol efflux study is to investigate a
possible mechanism for this inverse relationship. Since one
of the principal cells involved in cholesterol efflux are
endothelial cells, we undertook this study using primarily
an immortalized human endothelial cell line, EA.hy926, as
the model system. We also used murine RAW 264.7 macro-
phages to study the mechanisms involved in the efflux
process by HSA.2. Methods
2.1. Materials
Immortalized human vein endothelial cells (EA.hy926)
were generously provided by Dr. Cora-Jean S. Edgell
(University of North Carolina, Chaphill, NC) and murine
RAW264.7 macrophages were obtained from AmericanType Culture Collection (ATCC, Manassas, VA). Dulbec-
co’s modified Eagle’s medium (DMEM), fetal bovine se-
rum (FBS), Hank’s buffer saline solution, and all other
tissue culture supplies were purchased from Invitrogen Life
Technologies Inc. (Grand Island, NY). Bovine serum al-
bumin (BSA, fatty acid free), HSA (fatty acid free), oval-
bumin, gelatin, type I collagen, 8-(4-Chlorophenylthio)
adenosine3V:5V-cyclic monophosphate (CPT-cAMP) and
Cibacron coupled to Sepharose 6B were purchased from
Sigma Chemical Co. (St. Louis, MO). Human apoA-I was
purchased from Calbiochem (La Jolla, CA). 1-2n-[3H]cho-
lesterol (specific activity 40–60 Ci/mmol) was from Perkin
Elmer Life Science Research Products (Norwalk, CT). Vent
DNA polymerase was from New England Biolabs (Beverly,
MA). Plasmid vector, pHiL-D2 and a yeast strain, Pichia
pastoris were purchased from Invitrogen Corp. (San Diego,
CA). Lipidex-1000 was from Packard Instruments (Meri-
den, CT). BCA protein assay kit for quantification was from
Pierce Co. (Rockford, IL).
2.2. Synthesis and purification of recombinant HSA and its
various mutants
For our studies, we synthesized recombinant wild-type
HSA (wtrHSA) and the following single and double mutants
that were chosen based upon earlier studies of steroids and
digoxin binding to HSA mutant proteins [13]. The mutants
studied were K195M, K199M, F211V, W214L, R218A,
R218M, F242V, R257M, Y411A, R410A, R410M, R410Q/
Y411W, R410M/Y411F, Y411F, Y411L, W214L/Y411W,
and R410A/Y411A.
Specific mutations were introduced into the HSA-coding
region in a plasmid vector containing the entire HSA coding
region as described previously [14,16,26]. The experimental
methods consist of the following steps.
2.2.1. Cloning of HSA coding region
With human liver cDNA as the template, the entire
coding region of the HSA gene, including the native signal
sequence, was amplified by polymerase chain reaction
using Vent DNA polymerase. The resulting DNA fragment
was inserted into the plasmid vector pHiL-D2 using stand-
ard cloning techniques. pHiL-D2 is a shuttle vector that
can be manipulated by cloning in Escherichia coli and
that can also be used to introduce genes into yeast spe-
cies P. pastoris by homologous recombination. Specific
mutations were introduced into the HSA coding region
using site-directed mutagenesis as described previously
[14,16,26].
2.2.2. Expression of recombinant HSA
Each pHiL-D2 expression plasmid contained a metha-
nol-inducible promoter upstream of the HSA coding region.
For each expression plasmid, a yeast clone that contained
the expression cassette stably integrated into the yeast
chromosomal DNA was isolated. The native HSA signal
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rected high-level secretions of mature HSA into the growth
medium.
2.2.3. Verification of DNA sequence of HSA clones
The total genomic DNA from each P. pastoris clone used
to produce a particular HSA species was isolated using
standard techniques. The genomic DNA isolated from each
clone was used as template to amplify the entire HSA
coding region by polymerase chain reaction. For each clone,
the entire HSA coding region was sequenced using the
dideoxy chain termination technique, and the translation
product corresponding to this sequence matched a previ-
ously published cDNA of HSA at all amino acid positions
except for the mutation introduced into a particular HSA
mutant.
2.2.4. Purification of recombinant HSA
The secreted HSA was isolated from the growth medium
as follows. The medium was brought to 50% saturation
with ammonium sulfate at room temperature. The temper-
ature was then lowered to 4 jC, and the pH was adjusted to
4.4, the isoelectric point of HSA. The precipitated protein
was collected by centrifugation and resuspended in distilled
water. Dialysis was carried out for 48 h at 4 jC against
100 volumes of distilled water, followed by 24 h against
100 volumes of phosphate-buffered saline (PBS, 150 mM
NaCl, 40 mM phosphate, pH 7.4). The solution was loaded
onto a column of Cibacron blue immobilized on Sepharose
6B. After washing the column with 10 bed volumes of
PBS, the HSA was eluted with 3 M NaCl. The eluent was
dialyzed into PBS and passed over a column of Lipidex-
1000 to remove hydrophobic ligands possibly bound to
the HSA [14]. The resulting protein migrated as a single




EA.hy926 endothelial cells, seeded in 96 collagen-coated
wells, were maintained in DMEM supplemented with 10%
FBS, 0.1 mM sodium hypoxanthine, and 16 AM thymi-
dine at 37 jC, 5% CO2 and 95% air. This specific cell line
was derived from human umbilical vein endothelial cell
(HUVEC) by fusion with a relatively undifferentiated A549/
8 cell line which has been characterized to possess nor-
mal human endothelial cell properties [27–30]. Murine
RAW264.7 macrophages were also grown and maintained
in DMEM supplemented with 10% FBS. Upon reaching
confluency, cells were labeled with [3H]cholesterol and
assayed for cholesterol efflux.
2.3.2. [3H]cholesterol efflux assay
The labeling media was first prepared by concentrating
1-2n-[3H]cholesterol (40–60 Ci/mmol) under vacuum andresolubilizing in ethanol so that the final concentration of
ethanol did not exceed 0.1% of the final media concen-
tration. This [3H]cholesterol–ethanol solution (20 ACi/ml)
was dissolved into the culture medium supplemented with
5% FBS and added to the cells for 48 h to equilibrate
cellular cholesterol pools. Efflux was carried out by washing
the labeled cells twice with DMEM containing 2 mg/ml
BSA and twice with DMEM alone. The washed radio-
labeled cells were incubated at 37 jC with DMEM in the
presence or absence of various cholesterol acceptors for
various time intervals, using an orbital shaker. At the
indicated time interval, 50 Al of incubation medium was
taken and mixed with 100 Al of PBS containing 2 mg/ml
BSA. The mixture was centrifuged at 10,000 rpm, 5 min and
100 Al of supernatant was used for radioactivity counting.
At the end of incubation, cells were washed once with PBS
containing 2 mg/ml BSA and twice with PBS alone fol-
lowed by lysis with 0.2 ml of 0.1 N NaOH. Aliquots were
taken for radioactivity counting by liquid scintillation coun-
ter (Packard Tri-Carb 1500 liquid Scintillation System) and
cellular cholesterol efflux was expressed as cpm/mg cell
protein, as well as percent of total cholesterol released into
medium (percent efflux=(medium cholesterol/cell +medium
cholesterol)100). Total protein concentration was de-
termined according to the modified Biuret protein assay
method.
2.4. Statistical analysis
All data were presented as meanF S.E. Statistical differ-
ences were analyzed using analysis of variance (ANOVA) or
paired t-test with the level of significance set at 0.05.3. Results
3.1. HSA stimulates cholesterol efflux in a concentration-
and time-dependent manner
Initial studies were performed to determine an optimal
concentration of HSA and incubation time on cholesterol
efflux. After 48 h of [3H]cholesterol labeling, cells were
replenished with media containing various concentrations of
HSA. An aliquot of medium was taken at the 30-, 60-, and
90-min interval of the incubation, and the radioactivity was
measured. As illustrated in Fig. 1, HSA promoted choles-
terol efflux in a concentration- and time-dependent manner
within an optimal concentration of 10 mg/ml at 90 min. At
the 10 mg/ml concentration, efflux increased 4-fold at 30
min, 9-fold at 60 min, and 12-fold at 90 min compared to
the DMEM control, respectively. At the 90-min incubation
time, efflux increased 8-fold at 1 mg/ml HSA concentration,
10-fold at 5 mg/ml, 12-fold at 10 mg/ml, and 18-fold at 40
mg/ml. Efflux became less responsive at HSA concentration
of 40 mg/ml or 588 AM, which approximated the physio-
logical concentration of HSA at all time intervals. Thus, in
Fig. 2. Effect of HSA, BSA, ovalbumin, and gelatin on cholesterol efflux.
Cells were cultured and labeled with [3H]cholesterol for 48 h as described
in Fig. 1. Various acceptor proteins (HSA, BSA, ovalbumin, and gelatin)
were used at the 10 mg/ml concentration for the efflux study at 90-min
incubation time. Results are expressed as radioactivity (cpm) per milligram
of cell protein. The values represent the meanF S.E. from three inde-
pendent experiments performed in triplicate. *P < 0.05 vs. DMEM.
Fig. 1. Effect of various HSA concentrations and incubation time on
cholesterol efflux. Endothelial cells were cultured and labeled with
[3H]cholesterol (20 ACi/ml) for 48 h. Cells were washed and incubated
with DMEM containing various amounts of HSA (2.5, 5, 10, 40 mg/ml) for
different incubation times (30, 60, and 90 min). Aliquots of the medium
were taken at the designated time intervals to assess cholesterol efflux.
Results are expressed as radioactivity (cpm) released into the media per
milligram of cell protein. The values represent the meanF S.E. from three
independent experiments performed in triplicate.
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tion time were used.
3.2. HSA-mediated cholesterol efflux is specific
In order to determine whether the efflux observed from
endothelial cells is the result of a specific interaction
between HSA and cholesterol, we investigated the effects
of BSA, chicken ovalbumin (OVA) and gelatin on choles-
terol efflux. After 48 h of labeling, cells were replenished
with media containing 10 mg/ml of HSA, BSA, ovalbumin,
or gelatin. An aliquot of medium was taken at 90-min
interval of the incubation, and the radioactivity was meas-
ured. As shown in Fig. 2, HSA significantly increased
cholesterol efflux compared to untreated control (DMEM)
at both time intervals. On the other hand, gelatin, a matrix
protein, displayed little effect on cholesterol efflux, while
BSA and ovalbumin showed a small degree of stimulation
compared to the untreated DMEM control (gelatin: 1.3-fold;
ovalbumin: 3.4-fold; BSA: 7.9-fold higher efflux vs.
DMEM control at the 90-min incubation time). The differ-
ences in cholesterol efflux observed between BSA and HSA
is presumably due to a 76% amino acid sequence homology
and thus provides an explanation for the different choles-
terol efflux efficiency between HSA and BSA [1]. However,
ovalbumin does not have sequence homology with HSA but
its high content of a-helixes may have contributed to the
slight increased in cholesterol efflux. Taken together, the
effect of HSA on cholesterol efflux appears to be a specific
event.
The ability of apoA-I to promote cholesterol efflux from
cultured cells is well documented [8,31–34]. To estimate
the degree of HSA’s contribution toward cholesterol efflux,we compared the efflux rate mediated by HSA to that of
apoA-I (Fig. 3). As expected, reconstituted apoA-I exceeded
cholesterol efflux efficiency compared to equal molar con-
centration (i.e. 1 AM) of wtrHSA (168F 2%, P < 0.05 vs.
HSA). The data indicates that apoA-I is a major cholesterol
acceptor and possibly a major contributor toward peripheral
cholesterol efflux. However, as previously mentioned, we
believe that HSA may be as important as apoA-I in
cholesterol efflux because of its high plasma concentration.
The approximate mean HSA concentration in human plasma
is 600 AM in contrast to apoA-I which is 55 AM. To
determine whether HSA and apoA-I-mediated efflux is
additive to each other, we incubated cells in the media
containing equimolar concentration of HSA and apoA-I as
cholesterol acceptor. Interestingly, HSA- and apoA-I-medi-
ated cholesterol efflux showed that two processes are
additive, indicating that the two cholesterol efflux systems
employ totally separate processes.
3.3. HSA-mediated cholesterol efflux occurs via a cAMP-
independent and a relatively temperature-insensitive path-
way
At least two independent peripheral cholesterol efflux
pathways have been described [31]. One is the apoA-I-
mediated process, which is regulated by lipid-poor HDL and
is cAMP dependent. This pathway involves the transport of
cholesterol via ABC (ATP-binding cassette transporter) A1.
The other pathway is a nonspecific diffusion-mediated
cholesterol efflux from cell surface. This pathway is regu-
Fig. 4. Effect of cAMP on HSA-mediated cholesterol efflux. EA.hy926 endothelial
in the presence of HSA or apoA-I (1 and 2.5 AM) and compared to cells incubated
protein. The values represent the meanF S.E. from three independent experimen
Fig. 3. Effect of apoA-I and HSA on cholesterol efflux. Cells were
cultured and labeled as described in Fig. 1, except an equal molar
concentration of apoA-I (1 AM), wtrHSA (1 AM), and apoA-I +wtrHSA
(1 AM each) were used for the efflux study and compared. Radioactivity
released into the media was normalized to milligrams of cell protein
and expressed as a percent of total 3H-radioactivity (percent of total
efflux=[medium cholesterol/(cell +medium cholesterol)100]). Values rep-
resent the meanF S.E. from three independent experiments performed in
triplicate.
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BSA, and is not cAMP dependent. To elucidate whether
cAMP is involved in HSA-mediated cholesterol efflux, we
added the cell-permeable CPT-cAMP to our endothelial
cells and performed the efflux assay. Our results, as shown
in Fig. 4, indicated that incubation of endothelial cells with
1 and 2.5 AM HSA in the presence of 0.1 mM CPT-cAMP
had no significant stimulatory effect on the efflux rate when
compared to cells incubated with HSA without CPT-cAMP.
On the other hand, the presence of 0.1 mM CPT-cAMP
increased apoA-I-mediated cholesterol efflux by 55% and
44% at 1 and 2.5 AM, respectively, when compared to cells
incubated with apoA-I without CPT-cAMP (P < 0.05 vs.
cells without cAMP). These results suggest that HSA-
mediated cholesterol efflux is not cAMP dependent and,
therefore, may possibly represent a nonspecific diffusion-
mediated cholesterol efflux process. To validate our find-
ings, we used the murine RAW264.7 macrophage cell line,
which is known to be deficient of ABCA1 protein expres-
sion, to study the effects of ABCA1 expression on HSA and
apoA-I-mediated cholesterol efflux. cAMP is known to
induce apoA-I-mediated cholesterol efflux by stimulating
ABCA1 expression in RAW264.7 cells [35]. Our result as
shown in Fig. 5 indicated that cAMP did not have any effect
on HSA-mediated cholesterol efflux in contrast to apoA-I-
mediated cholesterol efflux, confirming our results above
with the endothelial cells.
To further characterize the pathway by which HSA
mediates cholesterol efflux, the effect of temperature on
HSA-mediated cholesterol efflux in [3H]cholesterol-loaded
endothelial cells were studied and compared to the apoA-I-cells were cultured and labeled as described in Fig. 1. Efflux was performed
with and without 0.1 mM of cAMP. Results are expressed as cpm/mg cell
ts performed in triplicate. *P< 0.05 vs. cells without cAMP.
Fig. 6. Arrhenius plot of HSA-mediated and apoA-I-mediated cholesterol
efflux. Cells were cultured and labeled as described in Fig. 1. Cells were
incubated at temperatures of 4, 15, 25, 30, and 37 jC in DMEM medium
containing 1 AM HSA or apoA-I and efflux was determined over a 90-min
incubation period. Radioactivity released into the media was normalized to
milligrams of cell protein and converted as a percent of total 3H-
radioactivity with the 37 jC temperature point set as 100%. For Arrhenius
plot, ln E was plotted against 1000/T, where E represents the percent of total
3H-radioactivity and T represents absolute temperature. The values
represent the meanF S.E. from three independent experiments performed
in triplicate.
Fig. 5. Effect of cAMP on apoA-I- and HSA-mediated cholesterol efflux
from RAW264.7 macrophage cells. Murine RAW264.7 macrophage cells
were cultured and labeled as described in Fig. 1. Cells were incubated for
10 h without or with 0.1 mM of cAMP. Cholesterol efflux was measured
during subsequent 90-min incubations with 1 AM HSA or apoA-I as
cholesterol acceptors. Radioactivity released into the media was normalized
to milligrams of cell protein and expressed as a percent of total 3H-
radioactivity (percent of total efflux=[medium cholesterol/(cell +medium
cholesterol)100]). The values represent the meanF S.E. from three inde-
pendent experiments performed in triplicate.
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be highly temperature sensitive, since it involves an active
transport of intracellular cholesterol to the cell surface via
caveolin-1 [31]. On the other hand, nonspecific diffusion-
mediated cholesterol efflux has been shown to be less
sensitive to temperature changes since it is believed to be
passive [31]. As shown in Fig. 6, an Arrhenius plot of
ln[percent of total radioactive cholesterol released into the
media] versus the reciprocal of temperature showed that
HSA-mediated cholesterol efflux was significantly less
temperature sensitive compared to the apoA-I-mediated
efflux. From the slope of the graph (Ea/2.3R), activation
energy values were calculated for apoA-I-mediated efflux
(42.07 kJ/mol) and for the HSA-mediated cholesterol efflux
(17.97 kJ/mol), respectively. The fact that an activation
energy for apoA-I-mediated process is far greater than that
of HSA-mediated process suggests that apoA-I-mediated
cholesterol efflux is much more energy dependent than
HSA-mediated cholesterol efflux. In summary, the data
further support that HSA-mediated cholesterol efflux is
independent of the apoA-I-mediated cholesterol efflux
process.3.4. Various HSA mutants display enhanced cholesterol
efflux
The diffusion-mediated efflux pathway is largely regu-
lated by the availability of cell surface cholesterol and its
affinity to various acceptors of not only lipoproteins, but also
plasma proteins. We have shown in this study that HSA can
modulate this process. To further characterize the nature of
cholesterol–HSA interaction, we examined the effect of
various HSA 2A and 3A subdomain mutants on cholesterol
efflux and compared to that of the wtrHSA. Endothelial cells
were labeled and incubated with 10 mg/ml of each HSA
mutants and wtrHSA for 90 min at 37 jC prior to the efflux
assay. As shown in Table 1, among the 17 different HSA
mutants, the mutants K195M, K199M, F211V, F242V,
Y411A, R410A/Y411A, Y411F, W214L/Y411W, and
R410Q/Y411W showed increased cholesterol efflux effi-
ciency compared to wtrHSA (117F 4%, 109F 6%, 120F
1%, 112F 9%, 116F 3%, 108F 3%, 135F 2%, 134F 6%,
and 140F 4%, respectively vs. wtrHSA). In contrast, HSA
mutants W214L, R218A, R218M, R257M, and R410M/
Y411F showed decreased cholesterol efflux efficiency com-
pared to wtrHSA (85F 3%, 97.4F 1%, 90F 13%,
89F 8%, 84F 7%, 93F 8%; and 95F 7%, respectively).
These results indicate that amino acids, Arg at positions 218,
257, and 410, Lys at positions 195 and 199, and Tyr at
Table 1
Subdomain 2A and 3A HSA mutation sites and mutants’ effects on cholesterol efflux
Subdomain 2A mutants





117.5*F 5.2 109.0*F 6.9 119.9*F 0.4 97.4F 0.4 89.7F 11.3 88.5*F 6.9 112.4*F 9.6 84.2*F 6.2
Subdomain 3A mutants





116.0*F 4.9 135.0*F 2.9 93.1F11.0 94.4F 9.8 133.6*F 10.3 139.2*F 8.0 107.5F 3.5 83.7*F 5.3
Cholesterol efflux mediated by HSA mutant proteins were expressed as percent of cholesterol efflux mediated by wtrHSA (set as 100%).
*P< 0.05 vs. wtrHSA.
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cholesterol interaction with HSA.4. Discussion
Many epidemiological studies have shown that high
plasma levels of HSA are associated with reduced risk for
CHD and mortality from CHD [19–25]. Despite this inverse
relationship between HSA levels and CHD, no definitive
biochemical mechanisms have been identified to explain
this relationship. We have chosen to study the role of HSA
on cholesterol efflux as a probable mechanism of action.
Previous studies have characterized HSA-mediated choles-
terol efflux from cultured human fibroblasts [7–9]. How-
ever, the contribution of HSA on cholesterol efflux has not
been thoroughly studied, including the mechanism for HSA-
mediated cholesterol efflux and the structure–function rela-
tionship of HSA on efflux. In our study, we have chosen to
investigate the properties of HSA-mediated cholesterol
efflux, namely the molecular mechanism for cholesterolefflux and the ligand binding property, using primarily
cultured human endothelial cells as the model system. We
chose endothelial cells since they are one of the principal
cells involved in the cholesterol efflux.
The result of this study clearly provides evidence that
HSA plays a role in cholesterol efflux and could be a major
contributor in the reverse cholesterol transport. HSA pro-
moted cholesterol efflux in a dose- and time-dependent
manner using physiologically relevant concentrations. This
effect was shown to be specific as other proteins including
gelatin, ovalbumin, and BSA showed either no, little, or
moderate effect on cholesterol efflux, respectively. On the
other hand, apoA-I-mediated efflux was shown to be supe-
rior to that of HSA-mediated efflux. However, considering
the high concentration of HSA in plasma (3.5–5 g/dl) and
the additive nature of HSA-mediated efflux to apoA-I-
mediated efflux, it is speculated that HSA may be a major
player in the reverse cholesterol transport from peripheral
tissue cells.
Based on previous studies and our findings, we specu-
lated that HSA may harbor at least two binding sites for
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specific for cholesterol since HSA is well known to act as
a carrier for a large number of hydrophobic ligands includ-
ing steroid hormones and hydrophobic drugs such as digi-
talis glycoside, which possess cholesterol-like structure.
Using various experimental techniques including spin-label-
ing, fluorescence, and NMR, these ligands were shown to
bind primarily to the 2A or 3A subdomain of HSA
[1,13,36]. In particular, one study using chemical modifica-
tion and fluorescence techniques showed that tryptophan,
tyrosine, arginine, and lysine residues of BSA are involved
in steroid binding [37]. Our previous studies with HSA
mutants reported that substitutions of tryptophan at position
214, phenylalanine at position 211, arginine at positions
218, 222, and 410, lysine at 195 and 199, and tyrosine at
position 411 in 2A and 3A subdomains affected HSA
interaction significantly with various ligands including thy-
roxine, warfarin, prostaglandin, digoxin, and bilirubin [11,
12,14–16,38–40]. To decipher whether these binding sites
of HSA may also be involved in cholesterol binding and
thus, in cholesterol efflux, we used a number of polymor-
phic forms of HSA in our investigation. We chose HSA 2A
and 3A mutants based on the presumption that cholesterol
would share the same binding sites as with digoxin and
steroids to HSA. Interestingly, HSA mutants with substitu-
tions for lysine 195 and 199 (K195M, K199M), phenyl-
alanine 211 and 242 (F211V, F242V), and tyrosine 411
(Y411A, Y411F, W214L/Y411W, R410A/Y411A, and
R410Q/Y411W) were more effective in promoting cellular
cholesterol efflux when compared to wtrHSA. On the other
hand, substitutions of arginine 218 and 257 for methionine
(R218M, R257M) or alanine (R218A) were less effective on
cholesterol efflux compared to wtrHSA, while substitution
of tryptophan 214 for leucine (W214L) exhibited no sig-
nificant effects on cholesterol efflux. These results suggest
that cholesterol interaction with HSA may be similar to the
interaction of steroids to HSA since the same amino acid
residues were found to have significant effect on steroid
and cholesterol binding to the protein. Also, these results
are consistent with earlier observations with other HSA
ligands such as thyroxine, bilirubin, and warfarin [11,12,
14–16,38–40]. Specifically, these results suggest that lysine
at position 195 and 199, phenylalanine 211 and 242, and
tyrosine at position 411 of wtrHSA resulted in unfavorable
effects on cholesterol efflux, so that mutant HSAs with
substitutions at these locations had increased cholesterol
efflux efficiency. Notably, HSA mutants with substitutions
for tyrosine 411 in the 3A subdomain, namely Y411A,
Y411F, W214L/Y411W, and R410Q/Y411W, were signifi-
cantly more effective in promoting cholesterol efflux when
compared to wtrHSA. These results are consistent with our
earlier observations with digoxin [13]. Interestingly, those
HSAmutants in the 3A subdomain, which increased digoxin-
binding affinity, also increased cholesterol efflux presumably
by enhancing cholesterol-binding affinity. These results sug-
gest that the main interaction between tyrosine 411 withcholesterol might involve the same stacking interactions
between the steroid backbone of cholesterol and the aromatic
rings of tyrosine, phenylalanine, or tryptophan as seen in
previous studies [13].
Another notable observation in our efflux study was with
the arginine at position 218 and 410 substitution in the 2A
and 3A subdomains. Previous site-directed mutagenesis
studies on HSA with various ligands showed that arginine
at position 218 in the 2A subdomain, a position homologous
to arginine at position 410 in subdomain 3A, had negative
interaction with small hydrophobic ligands such as thy-
roxine, warfarin, and bilirubin [14,16,38]. With a hydro-
phobic molecule like cholesterol, it is reasonable for us to
speculate that replacing arginine at position 218 and 410
with a less polar amino acid residue may enhance the
binding of HSA to cholesterol, therefore leading to more
efficient cholesterol efflux. In contrast, the substitutions of
arginine at position 218 and 410 for methionine (R218M,
R218A) or alanine (R410M, R410A) in our study showed
the opposite of what we expected based on previous studies
with digoxin, warfarin, bilirubin, and thyroxine [14,16,38].
The mutants R218A, R218M, R410A, R410M, and R410M/
Y411F showed slightly reduced efflux rates compared with
wtrHSA. These results suggest that arginine at positions 218
and 410 are not engaged in cholesterol binding, therefore
changing the arginine residues to a more hydrophobic and
smaller amino acid did not induce dramatic changes in
cholesterol efflux rates.
To examine the mechanism for the cholesterol efflux by
HSA, we investigated its effect on diffusion-mediated and
apoA-I-mediated cholesterol efflux. In the diffusion-medi-
ated pathway, cholesterol is adsorbed by various acceptors
including HDL and BSA [31]. The pathway is said to be
nonspecific and passive since it does not involve any spe-
cific interaction site on the cell membrane. In the other
pathway, cholesterol is removed by lipid-poor HDL via the
ABCA1 membrane protein and is cAMP dependent. To
differentiate the two possible mechanisms, we measured
HSA-mediated cholesterol efflux under different temper-
ature conditions. The apoA-I-mediated process is known to
be highly sensitive to temperature change, while diffusion-
mediated is less sensitive. Our data supports the diffusion-
mediated pathway as HSA-mediated efflux continued at 4
jC temperature, while apoA-I-mediated efflux was virtually
abolished. An Arrhenius plot of ln (natural log) efflux rate
against 1/temperature suggests that HSA and apoA-I-medi-
ated cholesterol effluxes are single-phase processes and the
slope of graphs indicate that apoA-I-mediated cholesterol
efflux requires much higher activation energy (42.07 kJ/
mol) compared to HSA-mediated efflux (17.97 kJ/mol),
supporting HSA-mediated efflux is diffusion-mediated proc-
ess. To further test this finding, we investigated the effect of
cAMP on cholesterol efflux. Since apoA-I-mediated efflux
is dependent upon cAMP, cAMP was added to endothelial
cells and ABCA1-deficient macrophages. Our results showed
cAMP did not stimulate HSA-mediated efflux unlike the
J.-S. Ha et al. / Biochimica et Biophysica Acta 1640 (2003) 119–128 127apoA-I-mediated efflux. Taken together, HSA-mediated
cholesterol efflux is a distinct process different from the
apoA-I-mediated process.
Although it is well accepted that apoA-I-mediated cho-
lesterol efflux involves phospholipids, it is not clear that
HSA-mediated efflux also involve phospholipids. Whether
HSA–phospholipid interactions may facilitate cholesterol
efflux will require further study. However, an earlier study
of lysolecithin binding to BSA has shown very weak bind-
ing interaction compared to fatty acids [41].
In conclusion, our studies have shown that HSA medi-
ates cholesterol efflux from endothelial cells at physio-
logically relevant concentrations. This process of efflux
may play a significant role in the reverse cholesterol trans-
port from periphery to the liver in maintaining cardiovas-
cular homeostasis. A broader implication of our study
supports the many epidemiologic observations that a rela-
tively low level of HSA is a risk factor for cardiovascular
disease. The relative contribution and importance of apoA-
1-mediated vs. HSA-mediated cholesterol efflux under
physiologic and pathologic conditions will require further
study. HSA-mediated cholesterol efflux may be quite sig-
nificant as it has been shown that in ABCA1 knockout mice,
cholesterol delivery from periphery to the liver is unchanged
compared to controls [42]. At the molecular level, one of the
unresolved issues is the nature of cholesterol efflux at the
plasma membrane–albumin interphase, which will require
further studies.Acknowledgements
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